We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Image: Bigstock
Catalyst Pharmaceuticals (CPRX) Jumps: Stock Gains 18.2%
Catalyst Pharmaceuticals, Inc. (CPRX - Free Report) was a big mover last session, as its shares rose over 18% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up almost 78% in the past one-month time frame.
The company has seen a mixed track record when it comes to estimate revisions of one increase and two decreases over the past 30 days, while the Zacks Consensus Estimate remained unchanged. Yesterdays’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Catalyst Pharmaceuticals currently carries a Zacks Rank #3 (Hold).
Catalyst Pharmaceuticals, Inc. Price
Catalyst Pharmaceuticals, Inc. Price | Catalyst Pharmaceuticals, Inc. Quote
A better-ranked stock in the Medical - Drugs space is Grifols, S.A. (GRFS - Free Report) , sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is CPRX going up? Or down? Predict to see what others think: Up or Down
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere
1 billion iPhones in 10 years but a new breakthrough is expected to generate more
than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging
phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020. Click here for the 6 trades >>